Mosunetuzumab (NCT05615636)

Name: Mosunetuzumab trial for Hodgkin Lymphoma (NCT05615636)
Uploaded: 2026-10-31T15:49:32.581Z
Duration: 1 min 13 s
Description: Mosunetuzumab trial for Hodgkin Lymphoma (NCT05615636). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05615636.

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL: a one-minute explainerNCT056156361 min

Mosunetuzumab trial for Hodgkin Lymphoma (NCT05615636). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with relapsed CD20-positive diffuse large B-cell lymphoma after at least one treatment, who cannot receive an autologous transplant. Grade 1–3a follicular lymphoma qualifies only for the safety group.

The idea: combine intravenous mosunetuzumab, polatuzumab and tafasitamab with oral lenalidomide. Mosunetuzumab connects T cells to lymphoma cells; polatuzumab carries a drug that disrupts cell division. Researchers assess safety and responses.

This phase 2 study plans 36 patients. Jason Westin leads it at MD Anderson in Houston, the single recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.